The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Inclusion Criteria: 1. Healthy volunteers aged 18 to 45 years old ; 2. Body mass index (BMI) above/equal 18 and below 28 kg/m2; 3. Child bearing potential, has a negative serum pregnancy test at screening period, and agrees to use contraceptions consistently and correctly in 14 days after dosing; 4. No smoking in a year before post-dosing of study drug; 5. Give their signed written informed consent to participate. Exclusion Criteria: 1. Subjects who have clinically significant abnormal laboratory test results; 2. Subjects with clinically significant abnormal ECG; 3. Subjects with cardiac or blood disease affecting the safety and pharmacokinetics; 4. Subjects with liver or renal disease affecting the safety and pharmacokinetics; 5. Subjects with digestive system disease affecting the safety of study drug; 6. Subjects with other acute or chronic disease affecting pharmacokinetics and product metabolism; 7. A positive hepatitis B surface antigen, hepatitis C or HIV test result; 8. History of hypersensitivity or allergy to any of the study drugs or to drugs of similar chemical classes; 9. Subjects, who in the opinion of the investigator, significantly abuse alcohol; 10. Drink in 36 hours before post-dosing of study drug; 11. Ingest any foods or beverages which may affect pharmacokinetics; 12. Drug abuse,a history of poisoning; 13. Smokers(use tobacco products in a year before post-dosing of study drug); 14. Subjects who had received other medications within 2 weeks prior to the first administration of Investigational Product,and the original and main metabolites were not completely eliminated; 15. Subjects who participated in any other clinical trials within 3 months prior to the administration of Investigational Product; 16. Subjects who had suffered from hemorrhage or blood donation over 200ml will be excluded; 17. Subjects over exercised accompanied with fatigue and muscle aches within 1 week period to the administration of Investigational Product; 18．Children,women who are pregnant,lactating,with childbearing potential and who are using acyeterions; 19．Haven't given their signed written informed consent to participate; 20．Subjects in the opinion of the investigator, could not participate in this study.